Product
Eyecyte-RPE™
1 clinical trial
5 indications
Indication
Retinal DiseaseIndication
Age-Related Macular DegenerationIndication
Age-related macular degenerationIndication
Geographic AtrophyIndication
Eye DisordersClinical trial
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular DegenerationStatus: Not yet recruiting, Estimated PCD: 2024-10-01